- SOLUBLE GUANYLATE CYCLASE ACTIVATORS
-
A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (" cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.
- -
-
Page/Page column 50
(2015/06/25)
-
- SOLUBLE GUANYLATE CYCLASE ACTIVATORS
-
A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (" cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceuticall acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.
- -
-
Page/Page column 41
(2015/06/25)
-
- SOLUBLE GUANYLATE CYCLASE ACTIVATORS
-
A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ("cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I , or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof
- -
-
Page/Page column 70; 71
(2011/12/14)
-
- Benzopyran or thiobenzopyran derivatives
-
The present invention provides novel benzopyran compounds, pharmaceutically acceptable salts thereof and stereoisomers thereof where the benzopyran compounds of the invention are compounds according to Formula I: The present invention further provides pharmaceutical compositions which possess anti-estrogenic activity and comprise at least one benzopyran compound of the invention and a method of treating breast cancer by administration of an effective amount of a benzopyran compound provided by the present invention.
- -
-
Page/Page column 281
(2010/01/31)
-
- An improved oxidation of an alcohol using aqueous permanganate and phase-transfer catalyst
-
The oxidation of a primary alcohol to the corresponding carboxylic acid via permanganate and phase-transfer catalyst has been modified to circumvent impurity formation incurred during the reaction. A safe, simple, and efficient process was developed which gave the required carboxylic acid in 77% isolated yield using sodium permanganate in the presence of tetraethylammonium hydrogen sulphate.
- Mahmood, Arshed,Robinson, Graham E.,Powell, Lyn
-
p. 363 - 364
(2013/09/08)
-
- Synthesis of Amino Acids with Modified Principal Properties 1. Amino Acids with Fluorinated Side Chains
-
The synthesis and characterization of chiral fluorinated analogues of norvaline and norleucine from commercially available starting materials are presented.Full experimental details for the synthesis of the following amino acids are given: (S)-4,4-difluoronorvaline, (S)-4,4,5,5,5-pentafluoronorvaline, (S)-5,5-difluoronorleucine, (S)-5,5,6,6,6-pentafluoronorleucine, and (S)-4,4,5,5,6,6,6-heptafluoronorleucine.These compounds were prepared with a view to obtaining new amino acids which possess physical and chemical properties so that their principal properties would be outside the range of variation of hitherto known amino acids.The principal properties are determined as latent variables in principal component analysis of molecular property descriptors.Two of the fluorinated amino acids, (S)-5,5,6,6,6-pentafluoronorleucine and (S)-4,4,5,5,6,6,6-heptafluoronorleucine were found to have principal properties outside the variation of previously characterized natural and synthetic amino acids.The principal properties, z parameters, for the five new fluorinated amino acids are given.
- Larsson, Ulf,Carlson, Rolf,Leroy, Jacques
-
p. 380 - 390
(2007/10/02)
-
